Clinical trialNCT03231306CompletedPhase 2Interventional

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

SponsorUniversity of Alabama at BirminghamEnrollment45Neurofibromatosis Type 1Plexiform Neurofibroma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults with NF1 and inoperable plexiform neurofibromas. The objective response to binimetinib is defined as ≥ 20% decrease in tumor volume reduction by 12 courses.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bruce Korf, MD, PhD
University of Alabama at Birmingham
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Children'S Hospital of Los Angeles
Los Angeles, California, United States
University of California at Los Angeles
Los Angeles, California, United States
Ucsf Benioff Children'S Hospital Oakland
Oakland, California, United States
University of California, San Diego - Rady Children'S Hospital
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Children'S National Medical Center
Washington D.C., District of Columbia, United States
Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
National Institute of Health - National Cancer Institute
Bethesda, Maryland, United States
Boston Children'S Hospital / Dana Farber Cancer Institute / Massachusetts General Hospital
Boston, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
New York University Medical Center
New York, New York, United States
Cinncinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
Ohio State University
Columbus, Ohio, United States
Oregon Health and Science University Hospital
Portland, Oregon, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Utah
Salt Lake City, Utah, United States
University of Washington - Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Binimetinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Nov 2017
Primary completion: 17 Apr 2024
Completion: 17 Apr 2024
Last update posted: 2 May 2025
Registered enrollment: 45
Registry id: NCT03231306

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.